

**Breaking new grounds: YUMAB GmbH at Science Campus Braunschweig-South
*Biotech pioneer exploits new potential for its antibody discovery platform in cooperation with the Helmholtz Centre for Infection Research***

Braunschweig, Germany, July 5, 2018 – YUMAB, a privately-held German biotechnology company that started out five years ago as a spin-off from the Technical University of Braunschweig (TUBS) to provide tailored solutions for fully human antibody discovery and development has expanded considerably and now moved its headquarter to the Science Campus Braunschweig-South to satisfy the need for more space, a superior infrastructure, and high-level scientific partnering. On June 26, YUMAB presented its new quarters and innovative business concept to business partners, customers, and campus neighbors during an open house day under the motto “breaking new grounds”.

Based on the profound expertise of YUMAB’s four founders Prof. Dr. Stefan Dübel, Dr. André Frenzel, Prof. Dr. Michael Hust, and Dr. Thomas Schirrmann in antibody phage display, the company was founded in 2012 with the goal to meet the demand for fully human antibodies in life science research and pharmaceutical development. Since then, the founders with each more than 28 years of research experience have built a unique technology platform for the generation of advanced recombinant fully human antibodies that cover a broad application spectrum, including therapeutics, diagnostics, and vaccines. In fee-for-service solutions and attractive flexible licensing options, YUMAB provides rapid, large-scale discovery and optimization of human monoclonal antibodies, custom libraries, antibody engineering, and tailored antibodies to difficult targets.

With Thomas Schirrmann as CEO, YUMAB started as *one-man company* but has quickly evolved to a solid 20+ employee corporation that operates globally. After five years, YUMAB is already a driver of the general trend in immunotherapy toward the use of fully human antibodies in therapeutic applications. Building on this successful development, YUMAB is now reaching out for the U.S. market and has opened its first subsidiary – YUMAB Inc. – last year in Atlanta, Georgia.

To further enable sustainable growth, YUMAB has now relocated its headquarter into larger accommodations of the renowned Helmholtz Centre for Infection Research (HZI) at the Science Campus Braunschweig-South, which is the largest academic research institute in Germany with focus on infectious diseases. The Scientific Director of the HZI – Prof. Dr. Dirk Heinz – considers the relocation of YUMAB GmbH as a true win-win situation for all partners with ample possibilities for new collaborations: “The easy access to specific human antibodies through YUMAB facilitates novel therapeutic approaches towards fighting antibiotic-resistant pathogens that pose an enormous threat in modern medicine.”

With his decision to move on campus, Thomas Schirrmann is convinced: "YUMAB will benefit from the scientific expertise as well as from the sophisticated research facilities and technologies available on-site which represent the ideal environment for the development of novel fully human antibodies for the treatment of infectious diseases and other therapeutic indications."

The significant potential for synergistic infectious disease research and development became apparent at YUMAB's open house day on June 26 during presentations by Thomas Schirrmann, Dirk Heinz, Stefan Dübel, Michael Hust and Lower Saxony's biotech network (BioRegionN) coordinator Dr. Maike Rochon. Throughout the day, approximately 90 visitors also used the opportunity for exchange during company tours and a leisurely barbecue. Thomas Schirrmann is confident: "After five successful years, we are excited to write the next chapter of innovative antibody technologies at the Science Campus Braunschweig-South."

Contact

YUMAB GmbH
Dr. Thomas Schirrmann, CEO
Phone: +49 (0)531-481170-0
Email: info@yumab.com
www.yumab.com

About YUMAB

YUMAB GmbH is a German biotechnology company founded in 2012 by scientists of the University of Braunschweig. YUMAB provides technologies, contract research, and services for the discovery and development of fully human antibodies for all therapeutic fields. In little more than five years, the company has become a global player in human monoclonal antibody development and drives the general trend in the immunotherapy space toward the use of fully human antibodies for therapeutic applications. Growing steadily with now over 20 employees, YUMAB has relocated its headquarters to the Science Campus Braunschweig-South in 2018 and has started a collaboration with the Helmholtz Centre for Infection Research (HZI) to exploit new growth potential in infectious disease R&D.



©YUMAB GmbH, 2018 (photo by Verena Meier)

YUMAB's management is looking forward to breaking new grounds in the development of novel antibody-based tools against infectious diseases at the Science Campus Braunschweig-South (left to the right):

Prof. Dr. Dirk Heinz (Scientific Director of the HZI), Prof. Dr. Michael Hust (Professor at the Technical University Braunschweig, TUBS), Silke Tannapfel (Administrative Director of the HZI), Dr. André Frenzel (CSO, YUMAB), Dr. Thomas Schirrmann (CEO, YUMAB), Prof. Dr. Stefan Dübel (Professor at TUBS & co-inventor of the phage display technology).



©YUMAB GmbH, 2018 (photo by Verena Meier)

“Breaking new grounds” – YUMAB celebrates its move with an open door day

On June 26 YUMAB opened its doors for campus neighbors, business partners and customers.